MedTrace Logo

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT03742921 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-12-06

No results posted yet for this study

Summary

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax.

1. Planned registration period 4 years
2. Planned surveillance period 5 years and 6 months

Conditions

  • Lymphoma, T-Cell, Peripheral

Interventions

DRUG

Istodax

Istodax

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Jinshu Cho, MD · Celgene

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2023-10-31
Completion
2023-10-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03742921 on ClinicalTrials.gov